Shanghai Universal Biotech Co Ltd
SZSE:301166
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Shanghai Universal Biotech Co Ltd
Revenue
Shanghai Universal Biotech Co Ltd
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
Shanghai Universal Biotech Co Ltd
SZSE:301166
|
Revenue
¥1.1B
|
CAGR 3-Years
0%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
|
Sinopharm Group Co Ltd
HKEX:1099
|
Revenue
¥575.2B
|
CAGR 3-Years
1%
|
CAGR 5-Years
5%
|
CAGR 10-Years
10%
|
|
|
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
Revenue
¥283.6B
|
CAGR 3-Years
7%
|
CAGR 5-Years
8%
|
CAGR 10-Years
10%
|
|
|
Jointown Pharmaceutical Group Co Ltd
SSE:600998
|
Revenue
¥157.7B
|
CAGR 3-Years
6%
|
CAGR 5-Years
8%
|
CAGR 10-Years
13%
|
|
|
C
|
China National Medicines Corp Ltd
SSE:600511
|
Revenue
¥52.5B
|
CAGR 3-Years
5%
|
CAGR 5-Years
5%
|
CAGR 10-Years
16%
|
|
|
Huadong Medicine Co Ltd
SZSE:000963
|
Revenue
¥33.1B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
4%
|
|
Shanghai Universal Biotech Co Ltd
Glance View
Shanghai Universal Biotech Co Ltd is a CN-based company operating in Health Care Providers & Services industry. The company is headquartered in Shanghai, Shanghai and currently employs 493 full-time employees. The company went IPO on 2021-12-28. Shanghai Universal Biotech Co Ltd is a China-based company mainly engaged in the supply of life science reagent products. The firm is also engaged in the supply of life science instruments and consumables and comprehensive technical services. The products supplied by the Company are mainly third-party brand products, supplemented by independent brand products. The life science reagents mainly include immunological reagents based on antibodies and antibody related reagents, as well as molecular biology reagents, cell biology reagents and biochemical reagents. The life science instruments and consumables include detection and analysis and sample preparation. The comprehensive technical services include experimental services, technical support services and other services.
See Also
What is Shanghai Universal Biotech Co Ltd's Revenue?
Revenue
1.1B
CNY
Based on the financial report for Dec 31, 2024, Shanghai Universal Biotech Co Ltd's Revenue amounts to 1.1B CNY.
What is Shanghai Universal Biotech Co Ltd's Revenue growth rate?
Revenue CAGR 5Y
7%
Over the last year, the Revenue growth was -9%.
